EGFR and non-small cell lung carcinoma: For NSCLC patients with EGFR-activating mutations, EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, gefitinib and dacomitinib, have dramatic therapeutic effects.